Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q1 FY24 Earnings Presentation
26 slides from Dishman Carbogen Amcis's earnings presentation, Aug 10, 2023
Slide 1: Exchange filing cover letter
10th August, 2023 To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, “Exchange Plaza”, C-1, Block G, Mumbai – 400 001. Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref.: Scrip Code N
Slide 2: Investor Presentation Quarter ended June 30th, 2023
Investor Presentation Quarter ended June 30 th , 2023
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward- looking statements, which may include statements relating to future results o
Slide 4: Dishman in a Nutshell
DISHMAN IN A NUTSHELL 4 decades 2,200+ Team Strength 25 28 Committed Members Embracing of Long-Standing Track Record in our Culture of Innovation & Sustainability CRAMS Dedicated Team/Scientist Working Multi-Purpose MANUFACTURING RESEARCH & DEVELOPMENT APIs in R&D - 950+ FACILITIES Globally and HIPO
Slide 5: Past Performance at a Glance
PAST PERFORMANCE AT A GLANCE Revenue from Operations (₹ mn) EBITDA and EBITDA % Cash Profit (₹ mn) EBITDA EBITDA % 4,499 24,129 4,087 21,407 5,519 20,586 20,436 19,120 4,976 3,374 3,260 3,902 4,142 2,538 2,744 26.8% 24.3% 18.2% 17.2% 14.3% FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22^ FY23^ FY19 FY2
Slide 6: Agenda
AGENDA 01 Quarter Highlights 02 Company Overview 03 Industry Overview
Slide 7: Quarter Highlights
QUARTER HIGHLIGHTS
Slide 8: Q1 FY24 Result Highlights
Q1 FY24 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN 3 . 8 % 7,234 + 3 1,266 5,406 904 17.5% 16.7% Q1FY23 Q1FY24 Q1FY23^ Q1FY24^ CASH PAT (₹ mn) & CASH EPS (₹) 5.7 4.5 897 693 Q1FY23 Q1FY24 Cash PAT = Adjusted PAT + (Depreciation - additional goodwill amortization) Adjusted PAT
Slide 9: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (₹ mn) Q1 FY24 Q1 FY23 YoY % FY23 Income from Operations (Net) 7,233.8 5,406.1 33.8% 24,129.2 COGS 1,633.1 931.7 75.3% 5,114.1 Employee Expenses 2,951.3 2,552.0 15.6% 10,352.7 Other Expenses 1,430.8 1,039.5 37.6% 5,340.4 EBITDA 1,218.6 882.9 38.0% 3,322.0 Margi
Slide 10: Revenue Breakup Analysis
REVENUE BREAKUP ANALYSIS Revenues (₹ mn) Q1 FY24 Q1 FY23 YoY % CARBOGEN AMCIS - Contract Research & Manufacturing Services1 5,612.1 3,634.9 54.4% CARBOGEN AMCIS- Cholesterol & Vit D Analogues2 931.2 634.6 46.7% DCAL India - NCE APIs & Intermediates3 383.4 622.5 -38.4% DCAL India - Quats & Generics3
Slide 11: Revenue Break-up
REVENUE BREAK-UP Total Operating Revenue – Q1 FY24 DCAL India - NCE APIs & Intermediates 12.9% 5.3% 4.2% DCAL India - Quats & Generics CARBOGEN AMCIS - Contract Research & Manufacturing 77.6% Services CARBOGEN AMCIS - Cholesterol & Vit D Analogues 10
Slide 12: Margin Analysis
MARGIN ANALYSIS EBITDA Margin %* Q1 FY24 Q1 FY23 CARBOGEN AMCIS - Contract Research & Manufacturing Services1 21.7% 19.4% CARBOGEN AMCIS- Cholesterol & Vit D Analogues2 18.4% 19.3% DCAL India - NCE APIs & Intermediates3 - 3.5% DCAL India - Quats & Generics3 7.0% 10.4% 1. Includes Switzerland, UK, Fr
Slide 13: Q1 FY24 Result Highlights
Q1 FY24 RESULT HIGHLIGHTS Net Revenue at Rs 7,233.8 mn in Q1 FY24 up by 33.8% YoY due to increase in CRAMS revenue from Switzerland and increase in revenue from Cholesterols & Vit D Analogues. Carbogen Amcis – CRAMS revenue increased by 54.4% YoY primarily due to higher commercial and Phase III deve
Slide 14: Company Overview
COMPANY OVERVIEW
Slide 15: About Us
ABOUT US Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical co
Slide 16: Key Strengths
KEY STRENGTHS Preferred global outsourcing Upfront investment of more partner with capabilities across the than ₹10,000 mn in large entire CRAMS value chain scale multi-purpose manufacturing capacities Strong chemistry skills The HIPO facility at Bavla, India is the largest HIPO facility in Asia. Di
Slide 17: Manufacturing Facilities
ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: Superior Chemistry Skills & Capabilities USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA 28 dedicated R&D labs with multiple shift R&D CARBOGEN AMCIS BV., Veenendaal, The CARBOGEN AMCIS operations, including HIPO labs (Sha
Slide 18: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS THE STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 19: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER CARBOGEN AMCIS (CA) STRONG RESEARCH CAPABILITIES § Focus is on supporting the development process from bench to market § Process research and development to the supply of APIs for preclinical studies, clinical trials and commercial use DISHMAN INDIA STRONG MANUFACTURING CAPAB
Slide 20: Cutting Edge HIPO Capabilities
CUTTING EDGE HIPO CAPABILITIES The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo lab and full- scale manufacturing units to cater to both small volume and large volume orders. State of the art containmen
Slide 21: Industry Overview
INDUSTRY OVERVIEW
Slide 22: Expected Global Spending by Therapy Areas in 2027
EXPECTED GLOBAL SPENDING BY THERAPY AREAS IN 2027 Oncology & Obesity expected to lead growth 5-Yr CAGR 2023-2027 Oncology 377 13-16% Immunology 177 3-6% Diabetes 168 3-6% Top 20 Therapy Areas (US$ bn) - 2027 Cardiovascular 126 1-4% Respiratory 92 3-6% CNS 81 2-5% Infectious diseases 74 2-5% GU sexua
Slide 23: Specialty: Market Share & Growth
SPECIALTY: MARKET SHARE & GROWTH Specialty medicines will represent about 43% of global spending in 2027 and 56% of total spending in developed markets 56% 49% 47% 43% 43% 40% 39% 36% 32% 27% 28% 24% 16% 16% 12% 10% 2012 2017 2022 2027 Pharmerging Other Developed Global 10 Developed Source: IQVIA In
Slide 24: For Further Queries
FOR FURTHER QUERIES Mr. Harshil Dalal Dishman Carbogen Amcis Ltd Global CFO Dishman Corporate House Email: harshil.dalal@dishmangroup.com Iscon-Bopal Road, Ambli Ahmedabad - 380058 Gujarat, Mr. Binay Sarda India Ernst & Young LLP www.imdcal.com P: +91 9920893764 Email: binay.sarda@in.ey.com
Slide 25: Press Release | Q1 FY24
Press Release| Q1 FY24 Dishman Carbogen Amcis Ltd. announces Q1 FY24 results CONSOLIDATED Q1 FY24 NET REVENUE AT RS. 723.4 CRORES Ahmedabad, India – August 9th, 2023 – Dishman Carbogen Amcis Ltd, a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from
Slide 26: Press Release | Q1 FY24
Press Release| Q1 FY24 § DCAL India – Quats & Generics revenue decreased by 40.3% YoY primarily due to higher supplies in this segment in the last quarter of the last financial year though more orders expected during the remaining nine months of the current financial year. § Adjusted EBITDA Margin a
Dishman Carbogen Amcis — Q1 FY24 Earnings Presentation on 6ix